{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-001792","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.714748+00:00","generated_at":"2026-05-15T08:38:36.102738+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entera Bio FY2025 net loss $11.4M, cash runway to mid-Q3 2026; EB613 Phase 3 submitted","bullets":["Net loss $11.4M ($0.25/sh) vs $9.5M in FY2024; R&D expenses $6.0M up from $4.5M.","Cash $14.9M at Dec 31, 2025 incl. $7.8M restricted for OPKO collab; operating cash burn $7.4M.","EB613 Phase 3 protocol submitted Mar 2026; FDA feedback expected late Apr 2026 with topline in H2 2028.","EB612 (LA-PTH) collaboration with OPKO expanded; IND filing expected late 2026.","EB618 (oral OXM) PK/PD validation complete; Phase 1 initiation dependent on injectable data by YE 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-001792","json":"https://secwatch.observer/filing/0001178913-26-001792.json","markdown":"https://secwatch.observer/filing/0001178913-26-001792.md","text":"https://secwatch.observer/filing/0001178913-26-001792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/0001178913-26-001792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/zk2634965.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:38:36.102738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5446078886b6c5bf5c253cefcbdde6b99729c9e","claim":"Entera Bio Ltd. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 27, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025 and business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/0001178913-26-001792-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}